STRS:NASDAQStratus Properties Inc. Analysis
Data as of 2026-06-12 - not real-time
$28.97
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Stratus Properties (STRS) is trading at a trailing PE of 10.85, well below the industry average of 33, and its price‑to‑book sits at 1.09, suggesting a potentially attractive valuation. However, the fundamentals are weak: revenue fell 24.8% year‑over‑year, operating margin is a staggering -197%, and operating cash flow is negative $31.9M despite a cash pile of $73.5M. The balance sheet shows $159.7M of debt against $73.5M of cash, yielding a debt‑to‑equity of 45.6%, which raises concerns about financial flexibility. The recent Q1 2026 earnings beat expectations with net income of $6.6M (≈$0.82 per share), yet the stock slipped 0.9% post‑release and is down 2.1% over the past month while the broader market rose 4.9%. Technically, the stock sits just above its 20‑day SMA (28.68) but below the 50‑day SMA (29.56), with a neutral trend, an RSI near 51, and a bullish MACD histogram (+0.09) supported by increasing volume. The price is near the calculated support of $26.27 and faces resistance around $30.17, while 30‑day volatility is high at 24% and beta is low at 0.71, indicating modest market sensitivity but elevated price swings.
Given the DCF‑derived fair value of $125.19, the market appears to price the stock at a deep discount, yet the combination of declining revenue, high leverage, and negative cash generation tempers enthusiasm. The “Extreme Greed” sentiment index (87.68) reflects market optimism, but the underlying financial health suggests caution. Investors should weigh the sizable valuation gap against the structural challenges before deciding on positioning.
Given the DCF‑derived fair value of $125.19, the market appears to price the stock at a deep discount, yet the combination of declining revenue, high leverage, and negative cash generation tempers enthusiasm. The “Extreme Greed” sentiment index (87.68) reflects market optimism, but the underlying financial health suggests caution. Investors should weigh the sizable valuation gap against the structural challenges before deciding on positioning.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Q1 earnings beat with positive net income
- Bullish MACD signal and rising volume
- Price trading below 50‑day SMA and near resistance
Medium Term
1–3 yearsCautious
Model confidence: 6/10
Key Factors
- Continued revenue decline and negative operating cash flow
- High debt relative to cash and equity
- Elevated volatility and limited upside without a clear turnaround
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Structural leverage and weak profitability metrics
- Sector cyclicality and concentration in Texas markets
- Discrepancy between DCF upside and realistic cash‑flow generation
Key Metrics & Analysis
Financial Health
Revenue Growth-24.80%
Profit Margin74.96%
P/E Ratio10.9
ROE6.24%
ROA-2.67%
Debt/Equity45.59
P/B Ratio1.1
Op. Cash Flow$-31996000
Free Cash Flow$83.2M
Industry P/E33.1
Technical Analysis
TrendNeutral
RSI51.0
Support$26.27
Resistance$30.17
MA 20$28.68
MA 50$29.56
MA 200$25.46
MACDBullish
VolumeIncreasing
Fear & Greed Index87.68
Valuation
Fair Value$125.19
GradeUndervalued
TypeValue
Risk Assessment
Beta0.71
Volatility24.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.